Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Shi Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8207-7479; OpenAlex author ID A5100362211. Sources: OpenAlex.

Their work

Papers
30 (first author 1, last author 15)
Trials
0
Grants
0
Labs led
1
Collaborators
50
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 8 papers · 2021: 3 papers · 2022: 2 papers · 2023: none · 2024: 4 papers · 2025: 5 papers · 2026: 2 papers

Papers 30

  1. Hypertemperature-Detonated Biomimetic Semiconductor Stromal Bombs for Enhanced Immunotherapy in Pancreatic Cancer. Last author DOI 10.1002/adma.202523468↗
  2. SRSF1-DLAT axis drives mitochondrial fusion to confer therapy resistance in diabetes-associated pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.drup.2026.101489↗
  3. SenExo-cCCT2 Reprograms Senescence Response and Anti-Tumor Immunity Following FOLFIRINOX Chemotherapy in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1002/advs.202508431↗
  4. Targeting cTRIP12 counteracts ferroptosis resistance and augments sensitivity to immunotherapy in pancreatic cancer. Last author DOI 10.1016/j.drup.2025.101240↗
  5. Targeting CLK1/SRSF7 axis-dependent alternative splicing sensitizes pancreatic ductal adenocarcinoma to chemotherapy and immunotherapy. Last author DOI 10.1016/j.drup.2025.101292↗
  6. TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis. Last author DOI 10.1158/0008-5472.can-24-4784↗
  7. Comprehensive analysis of the expression and prognostic value of ARMCs in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12885-024-13365-5↗
  8. Targeting the MCP-GPX4/HMGB1 Axis for Effectively Triggering Immunogenic Ferroptosis in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1002/advs.202308208↗
  9. cNEK6 induces gemcitabine resistance by promoting glycolysis in pancreatic ductal adenocarcinoma via the SNRPA/PPA2c/mTORC1 axis. Co-author DOI 10.1038/s41419-024-07138-y↗
  10. Necroptosis enhances 'don't eat me' signal and induces macrophage extracellular traps to promote pancreatic cancer liver metastasis. Last author DOI 10.1038/s41467-024-50450-6↗
  11. Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer. Last author DOI 10.1186/s12943-024-02128-2↗
  12. SRSF3-mediated regulation of N6-methyladenosine modification-related lncRNA ANRIL splicing promotes resistance of pancreatic cancer to gemcitabine. Last author DOI 10.1016/j.celrep.2022.110813↗
  13. Circular RNA circ-MTHFD1L induces HR repair to promote gemcitabine resistance via the miR-615-3p/RPN6 axis in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s13046-022-02343-z↗
  14. SHCBP1 interacting with EOGT enhances O-GlcNAcylation of NOTCH1 and promotes the development of pancreatic cancer. Last author DOI 10.1016/j.ygeno.2021.01.010↗
  15. CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer. Co-author DOI 10.1186/s13045-021-01072-8↗
  16. Construction and Validation of Novel Nomograms for Predicting Prognosis of Pancreatic Ductal Adenocarcinoma After Surgery According to Different Primary Cancer… Last author DOI 10.3389/fonc.2021.646082↗
  17. Development and validation of novel nomograms for predicting the survival of patients after surgical resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.2959↗
  18. Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.3425↗
  19. Anterior gradient 2 is a novel pro-tumor factor in pancreatic cancer under NF-κB subunit RelA trans-regulation that can be suppressed by eugenic acid. Co-author DOI 10.1016/j.biopha.2020.110830↗
  20. Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials. Co-author DOI 10.1186/s12885-020-06910-5↗
  21. LncRNA STXBP5-AS1 suppresses stem cell-like properties of pancreatic cancer by epigenetically inhibiting neighboring androglobin gene expression. Co-author DOI 10.1186/s13148-020-00961-y↗
  22. Identify key genes and pathways in pancreatic ductal adenocarcinoma via bioinformatics analysis Last author DOI 10.21203/rs.3.rs-16813/v1↗
  23. Identify key genes and pathways in pancreatic ductal adenocarcinoma via bioinformatics analysis Co-author DOI 10.21203/rs.3.rs-19826/v1↗
  24. SHCBP1 interacting with EOGT enhanced O-GlcNAcylation of NOTCH1 and promoted the development of pancreatic cancer . Last author DOI 10.21203/rs.3.rs-95104/v1↗
  25. RER1 enhances carcinogenesis and stemness of pancreatic cancer under hypoxic environment. Co-author DOI 10.1186/s13046-018-0986-x↗
  26. MicroRNA-300 promotes apoptosis and inhibits proliferation, migration, invasion and epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway b… First author DOI 10.1002/jcb.26270↗
  27. The over expression of long non-coding RNA ANRIL promotes epithelial-mesenchymal transition by activating the ATM-E2F1 signaling pathway in pancreatic cancer: … Co-author DOI 10.1016/j.ijbiomac.2017.03.123↗
  28. Cooperative down-regulation of ribosomal protein L10 and NF-κB signaling pathway is responsible for the anti-proliferative effects by DMAPT in pancreatic cance… Co-author DOI 10.18632/oncotarget.16557↗
  29. Hypoxia induces TWIST-activated epithelial-mesenchymal transition and proliferation of pancreatic cancer cells in vitro and in nude mice. Co-author DOI 10.1016/j.canlet.2016.09.027↗
  30. H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.2126↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zuwei Wang · 15 shared papers, 2020–2026 · strength 2.63
  2. Cheng‐Yu Liao · 15 shared papers, 2020–2026 · strength 2.48
  3. Yifeng Tian · 14 shared papers, 2016–2026 · strength 1.76
  4. Shun‐Cang Zhu · 7 shared papers, 2024–2025 · strength 1.34
  5. Yongding Wu · 6 shared papers, 2024–2025 · strength 1.16
  6. Chengke Xie · 6 shared papers, 2024–2025 · strength 1.14
  7. Ge Li · 5 shared papers, 2024–2026 · strength 1.04
  8. Can Yang · 9 shared papers, 2020–2022 · strength 1.03
  9. Long Huang · 9 shared papers, 2016–2022 · strength 0.97
  10. Ge Li · 6 shared papers, 2020–2025 · strength 0.84
  11. Hong-Yi Lin · 4 shared papers, 2024–2025 · strength 0.77
  12. Baiyong Shen · 8 shared papers, 2014–2022 · strength 0.76
  13. Yu Pan · 3 shared papers, 2025–2026 · strength 0.66
  14. Qian Zhan · 7 shared papers, 2014–2021 · strength 0.66
  15. Yanling Chen · 5 shared papers, 2014–2025 · strength 0.65
  16. Haoxiang Zhang · 3 shared papers, 2025 · strength 0.60
  17. Huixing Chen · 4 shared papers, 2017–2025 · strength 0.57
  18. Jiangzhi Chen · 5 shared papers, 2014–2024 · strength 0.53
  19. Yaodong Wang · 4 shared papers, 2016–2020 · strength 0.39
  20. Huatian Luo · 3 shared papers, 2020 · strength 0.33
  21. Chenghong Peng · 4 shared papers, 2014–2020 · strength 0.29
  22. Yao-Dong Wang · 3 shared papers, 2017–2020 · strength 0.27
  23. Yaodong Wang · 2 shared papers, 2021–2022 · strength 0.25
  24. Guanxiang Zhuo · 1 shared paper, 2025 · strength 0.23
  25. Chengke Xie · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.